Nektar reports upbeat opioid data; ALK reaps positive study on allergy immunotherapy;

@FierceBiotech: Join what is probably one of the fastest-growing LinkedIn groups in biotech, & learn the meaning of life... sciences. Join now | Follow @FierceBiotech

 @JohnCFierce: Man, oh man. Bluebird IPO busts out, raises $101M as biotech offerings turn red hot - $BLUE up 50%. News | Follow @JohnCFierce

@RyanMFierce: W/ $BLUE out, DMD drug developer Prosensa moves up in the biotech IPO queue, sets terms for $60M deal: More | Follow @RyanMFierce

 @EmilyMFierce: This week's issue of FierceBiotechResearch is out: Alzheimer's drug restores links in brain and more: This week's news | Follow @EmilyMFierce

> San Diego-based Nektar reported positive top-line results from a human abuse liability study for NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain. Release

> Copenhagen-based ALK says it reaped positive top-line results from the pivotal MERIT trial conducted with ALK's allergy immunotherapy tablet against house dust mite allergy. Release

> The experimental daratumumab--being developed by Genmab and Janssen--scored a durable response against multiple myeloma in a Phase I study. Report (reg. req.)

Medical Device News

@FierceMedDev: Editor's Corner: Germany's Epigenomics is betting its future on an early-detection colon cancer Dx. Feature | Follow @FierceMedDev

@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. Yesterday's story | Follow @DamianFierce

> Techne grabs Bionostics for $104M. Item

> Terumo adding 400+ jobs in R&D expansion. Report

> CryoLife eyes FDA approval for dissolving hemostat. Item

> Mirabilis nabs up to $13M for uterine fibroid device. Report

> OrthoSensor wins FDA nod for knee tech. Article

Pharma News

@FiercePharma: More Novo Nordisk bad news: Loses Prandin patent fight in U.S. Circuit court, $200m sales at risk. Report | Follow @FiercePharma

@EricPFierce: U.K. gets nervous on looming deadline for API certifications, outlines contingency plan. Yesterday's report | Follow @EricPFierce

> Biogen's impressive Tecfidera launch hits reimbursement, supply snags. Article

> Onglyza fails outcomes trial in a $1B hit for Bristol-Myers, AstraZeneca. Story

> Use prescription meds properly, save $200 billion a year. Report

Drug Delivery News

@MichaelGFierce: Self-propelled, spinning 'nano-necklaces' could pinpoint drug delivery. More | Follow @MichaelGFierce

> BD, JDRF partner to join artificial pancreas race. More

> Capsugel launches Lipidex platform for greater oral stability, potency. Item

> Teva grabs MicroDose respiratory biz with inhaled delivery platform. Article

> Drug-carrying 'nanovolcanoes' make precise delivery structures. Story

And Finally… Investigators say that a new study proves that an adequate amount of sleep reduces the risk of diabetes. Release

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.